← All trials
NCT05912296
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2023
- Primary completion
- Nov 30, 2024
- Completion date
- Mar 31, 2025
- First posted
- Jun 22, 2023
- Last posted
- Jun 22, 2023
- Enrollment
- 80
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Ribo Life Science Co. Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.